Early Stage Launches and Near-term Pipeline Products to Watch¹

| Product | Status | Catalysts to Watch |
|---|---|--|
| Miebo ^{®2} | Available in U.S. Filed in Canada 1Q23 | U.S. launch in process Canada approval expected 2024 |
| SiHy Daily | Launched SVS in ~50 countries, including China in 2Q23; Multifocal launched in U.S. and Japan | Geo-expansion continues Toric launch expected in 2024 |
| Lumify Expansion Opportunities | Eye Illuminations – Launching now in U.S. Preservative Free submitted 2Q23 | Preservative Free approval expected in 2024 Allergy submission expected 2024 |
| SeeLuma™ Fully Digital Surgical Visualization Platform (3D Microscope) | Available in U.S. and Western Europe | Additional countries expected to follow |
| eyeTELLIGENCE® Digital Platform | Beta software testing ongoing. Regulatory assessments complete | U.S. commercial release in process |
| IC-8 [®] Apthera™ | Available in select markets across Europe, as well as in Australia, New Zealand and Singapore | U.S. launch in process |
| MIMS® Minimally Invasive Surgical Procedure | Entered into exclusive European distribution agreement with Sanoculis | EU launch in process |
| enVista Envy™ enVista® Trifocal IOL | Canada, EU and U.S. submissions in process | Expect U.S. and Canada launch in 2024, EU 2025 (includes Toric versions and new EyeGility inserter) |
| enVista Aspire™ enVista® Extended Range Monofocal IOL | Available in U.S.; Canada submitted 1Q23 EU submitted 2Q23 | U.S. launch in process (includes Toric; new EyeGility inserter to be added in 2024) EU launch expected in 2024 with EyeGility inserter |
| enVista Beyond™ enVista® Extended Depth of Focus IOL | Clinical study expected to begin 2Q24 | Expect 2026 launch |

BAUSCH+LOMB